Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ADX-097

Other · developed by Akebia Therapeutics

Phase 2 Most advanced trial
AKBA Developer
1 Registered trials

What is ADX-097?

ADX-097 is an investigational drug studied in IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy.

At a glance

Drug type
Other
Therapy area
Immunology, Renal & urology
Developer
Akebia Therapeutics (AKBA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
FR7T6AM49L

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06419205 Phase 2 IgA Nephropathy Recruiting AKBA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

C3 (Complement Component 3) GlomerulopathyIgA NephropathyLupus Nephritis (LN)

More from Akebia Therapeutics

AKB-9090 Phase 1

Follow AKBA, the company behind ADX-097

See AKBA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AKBA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.